NZ774063A - Injectable composition - Google Patents
Injectable compositionInfo
- Publication number
- NZ774063A NZ774063A NZ774063A NZ77406319A NZ774063A NZ 774063 A NZ774063 A NZ 774063A NZ 774063 A NZ774063 A NZ 774063A NZ 77406319 A NZ77406319 A NZ 77406319A NZ 774063 A NZ774063 A NZ 774063A
- Authority
- NZ
- New Zealand
- Prior art keywords
- peptide
- injectable composition
- lyophilized preparation
- cyclodextrin
- cytotoxic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
- A61K40/4243—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018185532 | 2018-09-28 | ||
| PCT/JP2019/038223 WO2020067453A1 (ja) | 2018-09-28 | 2019-09-27 | 注射用組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ774063A true NZ774063A (en) | 2025-06-27 |
Family
ID=69951879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ774063A NZ774063A (en) | 2018-09-28 | 2019-09-27 | Injectable composition |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210338587A1 (https=) |
| EP (1) | EP3858377A4 (https=) |
| JP (1) | JP7162675B2 (https=) |
| KR (1) | KR20210068060A (https=) |
| CN (1) | CN113382746A (https=) |
| AU (1) | AU2019349329A1 (https=) |
| CA (1) | CA3113212A1 (https=) |
| MX (1) | MX2021003660A (https=) |
| NZ (1) | NZ774063A (https=) |
| WO (1) | WO2020067453A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024149926A (ja) * | 2021-08-06 | 2024-10-23 | ブライトパス・バイオ株式会社 | がんペプチドワクチンカクテル製剤、及びその製造方法 |
| EP4709424A1 (en) * | 2023-05-08 | 2026-03-18 | Integro Theranostics, LLC | Lyophilized products, pharmaceutical compositions, and kits comprising dye-peptide conjugates and derivatives |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4932199A (en) | 1998-07-31 | 2000-02-21 | Haruo Sugiyama | Cancer antigens based on tumor suppressor gene wt1 product |
| AR021849A1 (es) | 1998-09-30 | 2002-08-07 | Corixa Corp | Composiciones y metodos para la inmunoterapia especifica de wt1 |
| US20030072767A1 (en) | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| WO2002047474A1 (en) | 2000-12-13 | 2002-06-20 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
| EP1371664B1 (en) | 2001-03-22 | 2008-01-09 | International Institute of Cancer Immunology, Inc. | Wti modified peptide |
| US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
| WO2003106682A1 (ja) | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Hla−a24拘束性癌抗原ペプチド |
| ES2331305T3 (es) | 2002-09-20 | 2009-12-29 | International Institute Of Cancer Immunology, Inc. | Peptidos de wt1 de tipo sustituido. |
| US7353321B2 (en) | 2003-01-13 | 2008-04-01 | Sierra Logic | Integrated-circuit implementation of a storage-shelf router and a path controller card for combined use in high-availability mass-storage-device shelves that may be incorporated within disk arrays |
| KR101213015B1 (ko) | 2003-11-05 | 2012-12-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 로부터 유도된 hla-dr 결합성 항원 펩티드 |
| CA2548135C (en) | 2003-12-01 | 2014-04-22 | Sloan-Kettering Institute For Cancer Research | Synthetic hla binding peptide analogues and uses thereof |
| EP1844789B8 (en) | 2005-01-19 | 2014-10-08 | Sumitomo Dainippon Pharma Co., Ltd. | Emulsified composition for dilution and cancer vaccine composition |
| EP1951281B1 (en) | 2005-10-17 | 2015-04-15 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| CA2631292C (en) | 2005-11-30 | 2014-05-06 | International Institute Of Cancer Immunology, Inc. | Derivatised wt1 cancer antigen peptides and their use |
| WO2007120673A2 (en) | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
| WO2009046738A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| SG11201507883SA (en) * | 2013-03-29 | 2015-10-29 | Sumitomo Dainippon Pharma Co Ltd | Wt1-antigen peptide conjugate vaccine |
| ES2916834T3 (es) * | 2014-09-27 | 2022-07-06 | Sumitomo Pharma Co Ltd | Composición farmacéutica para inyección |
| CN107921106B (zh) | 2015-05-20 | 2023-09-08 | 住友制药株式会社 | Wt1抗原肽和免疫调节剂的组合用途 |
| US12383608B2 (en) | 2016-11-30 | 2025-08-12 | Sumitomo Pharma Co., Ltd. | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides |
-
2019
- 2019-09-27 JP JP2020549451A patent/JP7162675B2/ja active Active
- 2019-09-27 WO PCT/JP2019/038223 patent/WO2020067453A1/ja not_active Ceased
- 2019-09-27 CA CA3113212A patent/CA3113212A1/en active Pending
- 2019-09-27 NZ NZ774063A patent/NZ774063A/en unknown
- 2019-09-27 KR KR1020217011972A patent/KR20210068060A/ko active Pending
- 2019-09-27 AU AU2019349329A patent/AU2019349329A1/en not_active Abandoned
- 2019-09-27 MX MX2021003660A patent/MX2021003660A/es unknown
- 2019-09-27 US US17/279,807 patent/US20210338587A1/en active Pending
- 2019-09-27 CN CN201980077600.9A patent/CN113382746A/zh active Pending
- 2019-09-27 EP EP19864323.1A patent/EP3858377A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2020067453A1 (ja) | 2021-09-09 |
| AU2019349329A1 (en) | 2021-04-29 |
| CN113382746A (zh) | 2021-09-10 |
| JP7162675B2 (ja) | 2022-10-28 |
| EP3858377A1 (en) | 2021-08-04 |
| EP3858377A4 (en) | 2022-11-30 |
| WO2020067453A1 (ja) | 2020-04-02 |
| KR20210068060A (ko) | 2021-06-08 |
| MX2021003660A (es) | 2021-05-28 |
| US20210338587A1 (en) | 2021-11-04 |
| CA3113212A1 (en) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
| SA518390954B1 (ar) | لقاحات علاجية لفيروس الورم الحليمي البشري 18 | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| NZ733168A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| NZ737757A (en) | Peptide oligonucleotide conjugates | |
| CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
| TR201908291T4 (tr) | Şifrelenmiş bir tümör antijeninin ekspresyonunun arttırılmasına yönelik bir histon sap-ilmiği ve bir poli(a) sekansı veya bir poliadenilasyon sinyali içeren veya bunun için kodlama yapan nükleik asit. | |
| ZA201900367B (en) | Formulation of a peptide vaccine | |
| SG10201903349YA (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| BR112016024352A2 (pt) | ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria? | |
| EA202090751A2 (ru) | Новый метод иммунотерапии нескольких видов опухолевых заболеваний крови, таких как острый миелоидный лейкоз (омл) | |
| WO2017066706A8 (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| TW201613956A (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | |
| BR112016020364A2 (pt) | métodos para suscitar uma resposta de uma célula t antitumoral em um indivíduo tendo um tumor ou câncer e para aumentar a razão de células t efetoras sobre células t reguladoras no baço de um indivíduo | |
| MX2016002937A (es) | Vacuna oncologica. | |
| SG10201809701TA (en) | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent | |
| PH12017500450A1 (en) | Flavivirus virus like particle | |
| IN2014CH00391A (https=) | ||
| EP4253419A3 (en) | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | |
| NZ774063A (en) | Injectable composition | |
| ES2721159T3 (es) | Antígenos asociados a tumor independientes de MHC novedosos | |
| WO2016011432A3 (en) | Identification of immunogenic mhc class ii peptides for immune-based therapy | |
| MX2019012083A (es) | Nueva vacuna de peptidos contra la pcsk9. | |
| BR112017002193A2 (pt) | peptídeo derivado de urlc10 e vacina contendo o mesmo | |
| NZ595060A (en) | Treatment of cancer with immunostimulatory hiv tat derivative polypeptides |